That said, Recursion doesn't have a single therapy on the market yet. Over the past four years, the company has made little ...

It's called Recursion OS. Using 36 petabytes (36 million gigabytes) of biological and chemical data, Recursion OS can virtually test how a particular drug idea might perform in a real-world setting at ...

Recursion has more expressive power than iterative looping constructs. I say this because a while loop is equivalent to a tail recursive function and recursive functions need not be tail recursive.

Recursion Pharmaceuticals recently reported positive phase 2 results for REC-994, a potential treatment for symptomatic cerebral cavernous malformation, a disease caused by the abnormal formation ...

Recursion Pharmaceuticals, Inc. ( NASDAQ: RXRX) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 4:05 PM EDT ...

Is Recursion Still Being Made? We haven’t heard much about Recursion since the initial announcement from Netflix. However, it’s allegedly still in the works with Netflix, Rhimes, and Reeves.

Is Recursion Pharmaceuticals stock a buy on the sell-off? Risk-averse investors will probably be better off staying on the sidelines with Recursion Pharmaceuticals.

Recursion says REC-617 demonstrates dose-linear pharmacokinetics with rapid absorption and robust pharmacodynamic biomarker modulation. Recursion holds a webinar on Tuesday to discuss results from ...

Success for just one of Recursion's phase 2 programs could enable the stock to double within five years. However, the odds of success for phase 2 candidates aren't good. Risk-averse investors ...

Recursion Pharmaceuticals (NASDAQ: RXRX) is a clinical stage company that mixes healthcare with technology and artificial intelligence (AI). Its drug discovery platform, Recursion OS, is the key ...